Evidence map›Paper›PMID 31947841›Full record

ArticleCancers2020

Whole Genome Sequencing of Spontaneously Occurring Rat Natural Killer Large Granular Lymphocyte Leukemia Identifies JAK1 Somatic Activating Mutation.

T Tiffany Wang, Jun Yang, Shubha Dighe, Matthew W Schmachtenberg, Nathan T Leigh, Emily Farber, Suna Onengut-Gumuscu, David J Feith, Aakrosh Ratan, Thomas P Loughran and 1 more

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.3field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

T Tiffany WangDepartment of Medicine and University of Virginia Cancer Center, Division of Hematology & Oncology, University of Virginia School of Medicine, Charlottesville, VA 22908, USA.
Jun YangDepartment of Medicine and University of Virginia Cancer Center, Division of Hematology & Oncology, University of Virginia School of Medicine, Charlottesville, VA 22908, USA.
Shubha DigheDepartment of Medicine and University of Virginia Cancer Center, Division of Hematology & Oncology, University of Virginia School of Medicine, Charlottesville, VA 22908, USA.
Matthew W SchmachtenbergDepartment of Medicine and University of Virginia Cancer Center, Division of Hematology & Oncology, University of Virginia School of Medicine, Charlottesville, VA 22908, USA.
Nathan T LeighDepartment of Medicine and University of Virginia Cancer Center, Division of Hematology & Oncology, University of Virginia School of Medicine, Charlottesville, VA 22908, USA.
Emily FarberCenter for Public Health Genomics, University of Virginia, Charlottesville, VA 22908, USA.
Suna Onengut-GumuscuCenter for Public Health Genomics, University of Virginia, Charlottesville, VA 22908, USA.
David J FeithDepartment of Medicine and University of Virginia Cancer Center, Division of Hematology & Oncology, University of Virginia School of Medicine, Charlottesville, VA 22908, USA.ORCID 0000-0003-4981-1691
Aakrosh RatanCenter for Public Health Genomics, University of Virginia, Charlottesville, VA 22908, USA.ORCID 0000-0002-0782-3056
Thomas P LoughranDepartment of Medicine and University of Virginia Cancer Center, Division of Hematology & Oncology, University of Virginia School of Medicine, Charlottesville, VA 22908, USA.
Thomas L OlsonDepartment of Medicine and University of Virginia Cancer Center, Division of Hematology & Oncology, University of Virginia School of Medicine, Charlottesville, VA 22908, USA.
University of Virginia · US

Funding

Women's Oncology Program - WONP30CA044579 · NCI · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI Thomas P. Loughran · 1987 to 2026
$72.1M
Genomic Architecture of LGL LeukemiaR01CA178393 · NCI · UNIVERSITY OF VIRGINIA · PI Thomas P. Loughran, Aakrosh Ratan · 2016 to 2026
$6.5M
Summer Research Experience in Cancer(SuRE-C)R25CA206972 · NCI · UNIVERSITY OF VIRGINIA · PI ADRIAN J HALME, Hui Zong · 2017 to 2026
$2.0M
NCI NIH HHS P30 CA044579NCI NIH HHS P30CA044579NCI NIH HHS R01 CA178393NCI NIH HHS R01CA178393NCI NIH HHS R25 CA206972
6 · The paper itself

Abstract

Large granular lymphocyte (LGL) leukemia arises spontaneously in elderly Fischer (F344) rats. This rodent model has been shown to emulate many aspects of the natural killer (NK) variant of human LGL leukemia. Previous transplantation of leukemic material into young F344 rats resulted in several strains of rat NK (RNK) primary leukemic cells. One strain, RNK-16, was adapted into the RNK-16 cell line and established as an aggressive NK-LGL leukemia model. Whole genome sequencing of the RNK-16 cell line identified 255,838 locations where the RNK16 had an alternate allele that was different from F334, including a mutation in

Indexed as

activationF344JAK/STATleukemiamutationNK cellsRNK-16

Identifiers

PMID31947841
PMCPMC7017127
OpenAlexW2998079974

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.